202 related articles for article (PubMed ID: 27504794)
1. Adverse Reactions to Gadoterate Meglumine: Review of Over 25 Years of Clinical Use and More Than 50 Million Doses.
de Kerviler E; Maravilla K; Meder JF; Naggara O; Dubourdieu C; Jullien V; Desché P
Invest Radiol; 2016 Sep; 51(9):544-51. PubMed ID: 27504794
[TBL] [Abstract][Full Text] [Related]
2. Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study.
Soyer P; Dohan A; Patkar D; Gottschalk A
J Magn Reson Imaging; 2017 Apr; 45(4):988-997. PubMed ID: 27726239
[TBL] [Abstract][Full Text] [Related]
3. Safety of Gadobutrol: Results From 42 Clinical Phase II to IV Studies and Postmarketing Surveillance After 29 Million Applications.
Endrikat J; Vogtlaender K; Dohanish S; Balzer T; Breuer J
Invest Radiol; 2016 Sep; 51(9):537-43. PubMed ID: 26964075
[TBL] [Abstract][Full Text] [Related]
4. Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: results of a post-marketing surveillance study in Japan.
Ishiguchi T; Takahashi S
Drugs R D; 2010; 10(3):133-45. PubMed ID: 20945944
[TBL] [Abstract][Full Text] [Related]
5. Safety of gadoterate meglumine in over 1600 children included in the prospective observational SECURE study.
Chang DH; Pracros JP
Acta Radiol; 2019 Nov; 60(11):1450-1456. PubMed ID: 31027425
[TBL] [Abstract][Full Text] [Related]
6. Observational study on the incidence of nephrogenic systemic fibrosis in patients with renal impairment following gadoterate meglumine administration: the NSsaFe study.
McWilliams RG; Frabizzio JV; De Backer AI; Grinberg A; Maes BD; Zobel BB; Gottschalk A
J Magn Reson Imaging; 2020 Feb; 51(2):607-614. PubMed ID: 31287213
[TBL] [Abstract][Full Text] [Related]
7. Gadobutrol for contrast-enhanced magnetic resonance imaging in elderly patients: review of the safety profile from clinical trial, post-marketing surveillance, and pharmacovigilance data.
Endrikat J; Schwenke C; Prince MR
Clin Radiol; 2015 Jul; 70(7):743-51. PubMed ID: 25933719
[TBL] [Abstract][Full Text] [Related]
8. Safety of gadoterate meglumine in children younger than 2 years of age.
Farmakis SG; Hardy AK; Mahmoud SY; Wilson-Flewelling SA; Tao TY
Pediatr Radiol; 2020 May; 50(6):855-862. PubMed ID: 32055917
[TBL] [Abstract][Full Text] [Related]
9. Safety of gadobutrol, a new generation of contrast agents: experience from clinical trials and postmarketing surveillance.
Voth M; Rosenberg M; Breuer J
Invest Radiol; 2011 Nov; 46(11):663-71. PubMed ID: 21623211
[TBL] [Abstract][Full Text] [Related]
10. A Pharmacokinetics, Efficacy, and Safety Study of Gadoterate Meglumine in Pediatric Subjects Aged Younger Than 2 Years.
Scala M; Koob M; de Buttet S; Bourrinet P; Felices M; Jurkiewicz E
Invest Radiol; 2018 Feb; 53(2):70-79. PubMed ID: 28906338
[TBL] [Abstract][Full Text] [Related]
11. Incidence of immediate gadolinium contrast media reactions.
Prince MR; Zhang H; Zou Z; Staron RB; Brill PW
AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854
[TBL] [Abstract][Full Text] [Related]
12. A Structured Survey on Adverse Events Occurring Within 24 Hours After Intravenous Exposure to Gadodiamide or Gadoterate Meglumine: A Controlled Prospective Comparison Study.
Parillo M; Sapienza M; Arpaia F; Magnani F; Mallio CA; DʼAlessio P; Quattrocchi CC
Invest Radiol; 2019 Apr; 54(4):191-197. PubMed ID: 30379729
[TBL] [Abstract][Full Text] [Related]
13. [Multicenter analysis of tolerance and clinical safety of the extracellular MR contrast agent gadobenate dimeglumine (MultiHance)].
Herborn CU; Jäger-Booth I; Lodemann KP; Spinazzi A; Goyen M
Rofo; 2009 Jul; 181(7):652-7. PubMed ID: 19291607
[TBL] [Abstract][Full Text] [Related]
14. Safety of gadobenate dimeglumine (MultiHance): Summary of findings from clinical studies and postmarketing surveillance.
Shellock FG; Parker JR; Venetianer C; Pirovano G; Spinazzi A
Invest Radiol; 2006 Jun; 41(6):500-9. PubMed ID: 16763468
[TBL] [Abstract][Full Text] [Related]
15. Gadoxetate Disodium versus Gadoterate Meglumine: Quantitative Respiratory and Hemodynamic Metrics by Using Compressed-Sensing MRI.
Glessgen CG; Moor M; Stieltjes B; Winkel DJ; Block TK; Merkle EM; Heye TJ; Boll DT
Radiology; 2019 Nov; 293(2):317-326. PubMed ID: 31549944
[TBL] [Abstract][Full Text] [Related]
16. Safety assessment of gadobenate dimeglumine (MultiHance): extended clinical experience from phase I studies to post-marketing surveillance.
Kirchin MA; Pirovano G; Venetianer C; Spinazzi A
J Magn Reson Imaging; 2001 Sep; 14(3):281-94. PubMed ID: 11536405
[TBL] [Abstract][Full Text] [Related]
17. Baseline characteristics, diagnostic efficacy, and peri-examinational safety of IV gadoteric acid MRI in 148,489 patients.
Braun J; Busse R; Darmon-Kern E; Heine O; Auer J; Meyl T; Maurer M; Hamm B; de Bucourt M
Acta Radiol; 2020 Jul; 61(7):910-920. PubMed ID: 31739672
[TBL] [Abstract][Full Text] [Related]
18. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
Soulez G; Bloomgarden DC; Rofsky NM; Smith MP; Abujudeh HH; Morgan DE; Lichtenstein RJ; Schiebler ML; Wippold FJ; Russo C; Kuhn MJ; Mennitt KW; Maki JH; Stolpen A; Liou J; Semelka RC; Kirchin MA; Shen N; Pirovano G; Spinazzi A
AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633
[TBL] [Abstract][Full Text] [Related]
19. Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA).
Herborn CU; Honold E; Wolf M; Kemper J; Kinner S; Adam G; Barkhausen J
Invest Radiol; 2007 Jan; 42(1):58-62. PubMed ID: 17213750
[TBL] [Abstract][Full Text] [Related]
20. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.
Woolen SA; Shankar PR; Gagnier JJ; MacEachern MP; Singer L; Davenport MS
JAMA Intern Med; 2020 Feb; 180(2):223-230. PubMed ID: 31816007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
